Videos

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses a study of cobimetinib plus paclitaxel in triple-negative breast cancer (TNBC).

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses results of studies that investigated nivolumab and pembrolizumab in head and neck cancer.

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the current state of liver-directed therapy in metastatic colorectal cancer. 

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses challenges currently facing the ovarian cancer field.

Choosing Second-Line Therapy for Metastatic Kidney Cancer

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses immune targeting in ovarian cancer.

Matthew Galsky, MD, professor of Medicine at the Mount Sinai School of Medicine, discusses results of a study examining nivolumab monotherapy in metastatic bladder cancer.

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses a clinical trial investigating chemotherapy with durvalumab and tremelimumab in patients with non-small cell lung cancer (NSCLC).

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the current and future role of minimally invasive surgery in pancreatic cancer.

Gabriela Chiorean, MD, professor of medicine, discusses an ongoing phase I study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer.

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of<em> T790M </em>in <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC).

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer.&nbsp;

Adam M. Brufsky, MD, PhD, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Philip A. Philip, MD, PhD, professor of oncology and pharmacology, Karmanos Cancer Institute, Wayne State University, discusses how researchers in the pancreatic cancer field can learn from recent negative clinical trials.

Salah-Eddin Al-Batran, MD, medical oncologist and Director at the Institute of Clinical Cancer Research, Frankurt, Germany, discusses the findings of a study of paclitaxel with everolimus in gastric cancer.

Stefani Spranger, PhD, discusses how the presence or absence of CD8-positive T cells can affect treatment approaches for patients with melanoma.

Eileen M. O&rsquo;Reilly, MD, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.

Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.